In 2025, the U.S. FDA approved 46 new drug applications, including 34 new molecular entities and 12 biologics license applications. The new molecular entities include 31 small-molecule drugs and 3 oligonucleotides, while the biological license applications cover monoclonal antibodies, bispecific antibodies, antibody-dr...
Although the inhibitors targeting PARP are successfully applied in the clinical treatment of tumors, the further application of PARP inhibitors is limited by reasons such as multi-drug resistance, the DNA replication fork function recovery and relatively low proportion of BRCA1/2-mutant tumors. There have been relevant...
Yi-Ru Bai, Rui-Fang Li, Jing-Ru Kang et al.· European journal of medicina...· 0 citations
This review comprehensively summarises the development progress of new drugs approved in 2025, including molecular design, structural modification, structure-activity relationship, and enhancement of drug-like properties to offer valuable insights to pharmaceutical chemists and bring inspiration for future research.
Yi-Ru Bai, Rui-Fang Li, Xin-Hui Zhang et al.· Journal of Enzyme Inhibition...· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
